EP Patent

EP4227307A1 — Pyrazolopyrazine compounds as shp2 inhibitors

Assigned to Genzyme Corp · Expires 2023-08-16 · 3y expired

What this patent protects

Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.

USPTO Abstract

Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP4227307A1
Jurisdiction
EP
Classification
—
Expires
2023-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.